GAL and lung carcinoma: In patients with advanced lung cancer, IFN-γ-producing iNKT cell therapy, including Vα24+ iNKT cell and α-GalCer-pulsed APC (APC/Gal) therapy, correlated with clinical responses in 17 patients with non-small cell lung cancer [61].